22.22Open18.20Pre Close1 Volume337 Open Interest260.00Strike Price2.22KTurnover38.17%IV1.85%PremiumJan 17, 2025Expiry Date17.74Intrinsic Value100Multiplier25DDays to Expiry4.48Extrinsic Value100Contract SizeAmericanOptions Type-0.7410Delta0.0139Gamma11.68Leverage Ratio-0.1388Theta-0.1045Rho-8.65Eff Leverage0.2035Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet